Marie Sklodowska-Curie ITN-European Joint Doctorate.

12 PhD positions (Early Stage Researcher, ESR) on MOGLYNET-PhD programme in DRUG DISCOVERY AND DEVELOPMENT

Marie Sklodowska-Curie ITN-European Joint Doctorate MOGLYNET-programme in “Drug Discovery and Development” stems from six Doctoral Courses/Schools at five beneficiary institutions, providing research and training in the field of drug discovery and health. An active contribution of Industry in training activities is a relevant feature of the programme (www.moglynet.com).

Partner Universities and Doctorate Courses/Schools: University of Milan (Pharmaceutical Sciences; Experimental and Clinical Pharmacological Sciences), Italy – Coordinating University; University of Aberdeen (Graduate School in Life Sciences and Medicine) UK; University of Antwerp: (Antwerp Doctoral School), Belgium; University of Barcelona (University of Barcelona Doctoral School), Spain; University of Leiden (Graduate School of Leiden University Medical Center), The Netherlands.

Industrial partners for secondments activities: Bayer HealthCare Manufacturing, Italy; Biomax Informatics AG, Germany; HistoGeneX N.V., Belgium; KemoTech Srl, Italy; Linkcare Health Services, Spain; Pharmintraco Sagl, Switzerland; PPD Italy srl, Italy Associations: EIPG (European Industrial Pharmacists Group); EAS (European Atherosclerosis Society); EDQM (European Directorate for the Quality of Medicines).

Description

Modulation of glycolytic flux as a new approach for treatment of atherosclerosis and plaque stabilization will be the research topic of the programme through a multidisciplinary study. 12 ESR PhD positions are offered by the Consortium related to different and multidisciplinary projects strongly interconnected involving different state-of-the-art technologies and methodologies: Computational chemistry , Chemical synthesis, Bioanalytics and biophysics, In vitro biological evaluation, In vivo studies on pre-clinical models, Imaging, Metabolomics, Proteomics, Oxidative stress.

Each ESR will attend the following training activities: Training on advanced courses and soft and transferable skills provided by home University’s doctorate course/school; Training on PharmaSkills; Network-wide multidisciplinary training activities at the general Network Meetings/Summer Schools; Six-month secondment at one of the Partner Universities jointly awarding the doctoral degree to improve research methods complementary to those at home institution; Three/four-month secondment at one of the industrial partners where ESRs are expected to acquire Pharma Skills competences.

The ESR projects (see Admission/Application Process section)

ESR1 Design, synthesis and evaluation of inhibitors of a specific glycolytic enzyme target relevant for atherosclerosis therapy having improved pharmacological properties and bioavailability.

ESR2 In vitro studies on the effects of modulators/inhibitors of a specific glycolytic enzyme relevant for atherosclerosis therapy on cultured cells and neovessels formation and in vivo studies.

ESR3 Selection of new modulators/inhibitors of a specific glycolytic enzyme relevant for atherosclerosis therapy by in vitro evaluation and in an animal model of atherosclerosis.

ESR4 In vivo studies on the effects of inhibitors of a specific glycolytic enzyme relevant for atherosclerosis therapy on IP angiogenesis and on angiogenesis in vitro by following endothelial tube formation on matrigel.

ESR5 In vivo evaluation by optical and PET imaging of IP angiogenesis of atherosclerotic plaques, and validation of inhibitors of a specific glycolytic enzyme relevant for atherosclerosis therapy as fluorescent probes and PET tracers.

ESR6 In vivo studies on the effects of inhibitors of a selected specific glycolytic enzyme on atherosclerotic plaque composition and stability in a pre-clinical model and optical and morphometric image analysis.

ESR7 In vivo studies on the effects of selected specific glycolytic enzyme inhibitors on intraplaque angiogenesis and intraplaque haemorrhages in a pre-clinical model and in vivo PET imaging analysis.

ESR8 Design, synthesis, radiosynthesis and in vivo PET Imaging of atherosclerotic plaque with of selected inhibitors of a specific glycolytic enzyme.

ESR9 Computational analysis of a specific glycolytic enzyme relevant for atherosclerosis therapy, design of peptide modulators and in vitro test.

ESR10 Synthesis and structural characterization of peptide and peptidomimetics as modulators of a specific glycolytic enzyme relevant for atherosclerosis therapy.

ESR11 Studies of the role of inhibitors/modulators of a specific glycolytic enzyme relevant for atherosclerosis therapy in endothelial dysfunctionality associated to thromboembolic pulmonary disease

ESR12 Bioanalytical and proteomic approaches in the study of pathologic ECs dysfunctionality, oxidative stress and the effects of modulators of a specific glycolitic enzyme relevant for atherosclerosis therapy.

Research Fields

Computational Chemistry, Organic Synthesis, Medicinal Chemistry, Pharmacological Sciences, Biochemistry, Medical Sciences

Career Stage

Early stage researcher or 0-4 yrs (Post graduate)

Research Profiles

First Stage Researcher (R1)

Benefits

A 36-months employment contract, or tax free stipend with full social security coverage equivalent to an employment contract, including adequate and equitable social security provisions according to existing national legislation

Requirements and comments for additional job details

For specific requirements and details regarding the eligibility criteria, please consult the MOGLYNET website.

Please regard the Marie-Curie Mobility Rule: Candidates must not have resided or carried out their main activity (work, studies, etc.) in the country of their host organisation for more than 12 months in the 3 years immediately prior to the reference date.

Send us your application by visiting our website, http://www.moglynet.com and following the “Admission /Application Process”.

For specific questions, you can contact us via secretary@moglynet.com